CAR T cell therapy targeting CD70 for leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment made from your own immune cells, called CAR T cells, that are designed to find and attack leukemia cells with a specific marker called CD70. It may be an option if your leukemia has come back or not responded to standard treatments and you might be able to receive a stem cell transplant if this treatment helps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have acute myeloid leukemia (AML) or another type of leukemia that is CD70-positive and has not responded to treatment or has returned after treatment.
- Your leukemia cells must have at least 26% of the CD70 marker on them, confirmed by a lab test.
- You must be 75 years old or younger.
- You must have a donor identified for a possible stem cell transplant, or you have decided against having one.
- You must be in reasonably good health, with adequate kidney, liver, heart, and lung function.
- You cannot have active infections, other uncontrolled cancers, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a customized immune-cell treatment (CAR T) that targets CD70 on cancer cells in certain blood cancers. It may help people whose disease has returned or did not respond to standard treatments.
This early-phase trial tests a lab-made immune cell treatment (CAR T-cells) aimed at T-cell leukemia that has come back or did not respond. It may help by targeting leukemia cells with a specific marker (CD7), especially in patients who failed standard treatment.
This trial tests a new type of CAR T-cell therapy—a treatment that uses your own immune cells engineered to fight leukemia cells. It is designed for patients with B-cell acute lymphoblastic leukemia (ALL) that has come back or stopped responding to standard treatments, and whose leukemia cells have a specific marker called TSLPR.
This trial tests a new type of immune cell therapy (CAR T cells) for people with acute myeloid leukemia (AML) that has come back or not gone away after treatment. The therapy is designed to find and attack leukemia cells that have a specific marker called CD371.
This trial tests a special immune cell therapy (CAR T-cells) that targets a protein called CD70 on blood cancer cells. It is for children and young adults up to age 21 whose cancer has come back or hasn't gotten better with other treatments.
This trial tests an immune cell treatment (CAR-NK cells) targeting a protein called CD70 found on cancer cells. It's for people with T cell lymphoma or acute myeloid leukemia that has come back or not responded to other treatments.
Hear when a new Leukemia, Myeloid, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.